Cargando…
Into the Clinic With Nivolumab and Pembrolizumab
In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best p...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AlphaMed Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861376/ https://www.ncbi.nlm.nih.gov/pubmed/27026678 http://dx.doi.org/10.1634/theoncologist.2016-0099 |